Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of DA-5215 and DA-5215-R in Healthy Volunteers
NCT05376085Phase 1Unknown
- Sponsor
- Dong-A ST
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apremilast in psoriasis and psoriatic arthritis (PsA) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the plasma Concentration versus time curve (AUCt) at 48 hours and Peak Plasma Concentration (Cmax) at 48 hours. Status: unknown.
02
Drugs
apremilast
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05376085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376085.